GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UnicoCell Biomed Co Ltd (TPE:6794) » Definitions » Debt-to-Equity

UnicoCell Biomed Co (TPE:6794) Debt-to-Equity : 0.10 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is UnicoCell Biomed Co Debt-to-Equity?

UnicoCell Biomed Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$6.22 Mil. UnicoCell Biomed Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$62.02 Mil. UnicoCell Biomed Co's Total Stockholders Equity for the quarter that ended in Dec. 2024 was NT$684.61 Mil. UnicoCell Biomed Co's debt to equity for the quarter that ended in Dec. 2024 was 0.10.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for UnicoCell Biomed Co's Debt-to-Equity or its related term are showing as below:

TPE:6794' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08   Med: 0.11   Max: 0.2
Current: 0.1

During the past 8 years, the highest Debt-to-Equity Ratio of UnicoCell Biomed Co was 0.20. The lowest was 0.08. And the median was 0.11.

TPE:6794's Debt-to-Equity is ranked better than
57.82% of 1017 companies
in the Biotechnology industry
Industry Median: 0.14 vs TPE:6794: 0.10

UnicoCell Biomed Co Debt-to-Equity Historical Data

The historical data trend for UnicoCell Biomed Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UnicoCell Biomed Co Debt-to-Equity Chart

UnicoCell Biomed Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial 0.10 0.08 0.20 0.13 0.10

UnicoCell Biomed Co Quarterly Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.13 0.10 0.10 0.10

Competitive Comparison of UnicoCell Biomed Co's Debt-to-Equity

For the Biotechnology subindustry, UnicoCell Biomed Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UnicoCell Biomed Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where UnicoCell Biomed Co's Debt-to-Equity falls into.


;
;

UnicoCell Biomed Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

UnicoCell Biomed Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

UnicoCell Biomed Co's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


UnicoCell Biomed Co  (TPE:6794) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


UnicoCell Biomed Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of UnicoCell Biomed Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


UnicoCell Biomed Co Business Description

Traded in Other Exchanges
N/A
Address
Minquan East Road, 5th Floor, No. 13-20, Section 6, Neihu District, Taipei, TWN, 11494
UnicoCell Biomed Co Ltd is a biotechnology company. Its main business includes new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D.

UnicoCell Biomed Co Headlines

No Headlines